Merck & Co. (MRK)
(Delayed Data from NYSE)
$118.45 USD
+0.99 (0.84%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $118.28 -0.17 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Price, Consensus and EPS Surprise
MRK 118.45 +0.99(0.84%)
Will MRK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRK
Merck (MRK) Advances But Underperforms Market: Key Facts
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
MRK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
Other News for MRK
Columbia Dividend Income Fund Q2 2024 Investment Commentary
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease
NuCana plunges after trial setback for cancer drug
NuCana plunges amid trial setback for cancer drug
NuCana plunges despite trial setback for cancer drug